April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Result of Combination Therapy of Photodynamic Therapy and Intravitreal Ranibizumab Injection in Exudative Age-Related Macular Degeneration (amd)
Author Affiliations & Notes
  • H.-W. Kwak
    Ophthalmology, Kyung Hee University, Seoul, Republic of Korea
  • E.-S. Kim
    Ophthalmology, Kyung Hee University, Seoul, Republic of Korea
  • S.-Y. Yu
    Ophthalmology, Kyung Hee University, Seoul, Republic of Korea
  • Footnotes
    Commercial Relationships  H.-W. Kwak, None; E.-S. Kim, None; S.-Y. Yu, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 1911. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H.-W. Kwak, E.-S. Kim, S.-Y. Yu; Result of Combination Therapy of Photodynamic Therapy and Intravitreal Ranibizumab Injection in Exudative Age-Related Macular Degeneration (amd). Invest. Ophthalmol. Vis. Sci. 2009;50(13):1911.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To investigate the result of combination therapy of photodynamic therapy and intravitreal ranibizumab injection in Korean patients with exudative AMD

Methods: : We evaluated 13 eyes of 13 patients with exudative age-related macular degeneration. First day of treatment, photodynamic therapy and intravitreal ranibizumab injection was performed at the same time, then 2 more injection at an interval of 4 weeks. After this, visual acuity, foveal thickness, fundus autofluorescence, PHP examination was recorded, and additional treatment was done when it needed.

Results: : Average visual acuity (ETDRS) before treatment is 0.88, and 0.76, 0.60, 0.50, 0.56 after 1 month, 3 month, 6 month, 12 month after treatment. At 12 month after, Visual acuity improved by about 19.4 letters. Foveal thickness before treatment is 300um, and 167 um, 125 um, 141 um, 138 um after treatment. There is no specific differences in fundus autofluorescene finding before and after treatment. The change of metamorphopsia was measured by PHP. P-value increased and the area of metamorphopsia decreased. Total injection time is 4.21 during 12 month.

Clinical Trial: : www.ISRCTN.org CCT-NAPN-18335

Keywords: age-related macular degeneration • vascular endothelial growth factor • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×